SPRING BANK PHARMACEUTICALS, INC. (NASDAQ:SBPH) Files An 8-K Other EventsItem 8.01. Other Events.
On April 10, 2018, the Registrant issued a press release announcing expanded results from Part A of the Registrant’s Phase 2 ACHIEVE clinical trial of patients infected with chronic hepatitis B virus.A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release issued April 10, 2018. |
Spring Bank Pharmaceuticals, Inc. ExhibitEX-99.1 2 sbph-ex991_6.htm EX-99.1 sbph-ex991_6.htm Exhibit 99.1 Spring Bank Announces Expanded Inarigivir Data from the ACHIEVE Trial to Be Presented at The International Liver CongressTM *Results from full 24 weeks of dosing from the first two cohorts of Part A in the ongoing Phase 2 ACHIEVE trial in hepatitis B to be highlighted in oral and poster presentations *30% of patients in first two cohorts achieved >0.5log10 reduction in HBsAg *Additional benefit of >0.5log10 reduction in HBsAg observed in HBeAg high viral load patients when sequentially-dosed with tenofovir disoproxil fumarate *Dose and exposure-dependent effect of inarigivir on HBV DNA and HBV RNA demonstrated HOPKINTON,…To view the full exhibit click here
About SPRING BANK PHARMACEUTICALS, INC. (NASDAQ:SBPH)
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company’s SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. It also focuses on the use of SB 9200 in other viral diseases, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and latency and hepatitis delta virus (HDV), conducting preclinical research of additional SMNH product candidates or compounds as antiviral therapies and conducting early-stage research programs.
